Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(11):883; doi:10.1093/jnci/djh170
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ratliff, B.
Right arrow Articles by Seewaldt, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ratliff, B.
Right arrow Articles by Seewaldt, V. L.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

Brooke Ratliff, Eric C. Dietze, Gregory R. Bean, Cassandra Moore, Sam Wanko, Victoria L. Seewaldt

Affiliation of authors: Division of Oncology, Department of Medicine, Duke University Medical Center, Durham, NC

Correspondence to: Brooke Ratliff, MD, Division of Oncology, Department of Medicine, Duke University Medical Center, Box 3841, Durham, NC 27710 (e-mail: ratli006@mc.duke.edu)

The first 10% of the full text of this article appears below.

The article by Stearns et al. (1) provides evidence that the tamoxifen metabolite endoxifen (4-hydroxy-N-desmethyltamoxifen) is equipotent with 4-hydroxytamoxifen in inhibiting estradiol-stimulated MCF7 cell proliferation. Further, they show that paroxetine can potentially interfere with metabolism of tamoxifen . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Riccardo Ponzone, Nicoletta Biglia, and Piero Sismondi
J Natl Cancer Inst 2004 96: 883-884. [Extract] [Full Text] [PDF]

Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Ernst A. Lien, Per M. Ueland, and Per E. Lønning
J Natl Cancer Inst 2004 96: 884. [Extract] [Full Text] [PDF]

RESPONSE: Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
Vered Stearns, Michael D. Johnson, James M. Rae, Antonella Novielli, Pankaj Bhargava, Daniel F. Hayes, Zeruesenay Desta, and David A. Flockhart
J Natl Cancer Inst 2004 96: 884-885. [Extract] [Full Text] [PDF]